Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

BACKGROUND: We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present an updated pooled analysis with a longer follow‐up of 35.2 mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Zhou, Keshu, Zou, Dehui, Li, Dengju, Hu, Jianda, Yang, Haiyan, Zhang, Huilai, Ji, Jie, Xu, Wei, Jin, Jie, Lv, Fangfang, Feng, Ru, Gao, Sujun, Zhou, Daobin, Tam, Constantine S., Simpson, David, Wang, Michael, Phillips, Tycel J., Opat, Stephen, Fang, Cheng, Sun, Shaohui, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557885/
https://www.ncbi.nlm.nih.gov/pubmed/37705497
http://dx.doi.org/10.1002/cam4.6473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557885/
https://www.ncbi.nlm.nih.gov/pubmed/37705497
http://dx.doi.org/10.1002/cam4.6473

Ejemplares similares